Vaxart Inc. (VXRT) News
Filter VXRT News Items
VXRT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
VXRT News Highlights
- VXRT's 30 day story count now stands at 16.
- Over the past 27 days, the trend for VXRT's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
- BEAT, CORT and FOLD are the most mentioned tickers in articles about VXRT.
Latest VXRT News From Around the Web
Below are the latest news stories about Vaxart Inc that investors may wish to consider to help them evaluate VXRT as an investment opportunity.
VAXART, INC. (VXRT) Reports Q4 Loss, Lags Revenue EstimatesVAXART, INC. (VXRT) delivered earnings and revenue surprises of 0% and 69.55%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock? |
Vaxart Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial ResultsCompany begins 2022 with multiple active programs with data readouts expected this year Initial data from COVID-19 Phase II study expected in the first half of 2022 and data from several norovirus studies also expected this year Ended 2021 with $182.7 million in cash, cash equivalents and marketable securities SOUTH SAN FRANCISCO, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) issued its business update today for the fourth quarter and full year 2021, reporting forward mom |
Vaxart’s S-Only COVID-19 Vaccine Candidate Produces Strong-Cross Reactive Mucosal and Systemic Immune Responses in Non-Human PrimatesNewly published data demonstrates substantial cross-reactivity against multiple variants of COVID-19 S-only candidate is believed to be the first to demonstrate robust neutralizing antibody responses in mucosal sites, which is where primary infection occurs Vaxart’s S-only candidate induced a 1000-fold increase in nasal IgA responses to the variants, which could have substantial impact on reducing community transmission SOUTH SAN FRANCISCO, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- A new study p |
These 2 Stocks Carry a Lot of Risk, but Their Upside Is HugeRight now, I'm thinking of a biotech company with game-changing vaccine technology and a company whose successes are tied to the cryptocurrency market. The coronavirus pandemic put Vaxart's (NASDAQ: VXRT) name on the map. Vaxart's candidate still is in phase 2 trials. |
Earnings Preview: VAXART, INC. (VXRT) Q4 Earnings Expected to DeclineVAXART, INC. (VXRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
ImmunoGen (IMGN) Up on Licensing Deal With Lilly Worth $1.7 BImmunoGen (IMGN) inks a licensing agreement with Eli Lilly, granting the latter rights to develop and commercialize ADCs directed toward targets selected by Lilly. Stock up. |
Corcept's (CORT) Q4 Earnings Beat Estimates, Revenues MissCorcept's (CORT) earnings beat estimates in the fourth quarter of 2021 while revenues miss the same. |
Corcept Therapeutics (CORT) Q4 Earnings Beat EstimatesCorcept (CORT) delivered earnings and revenue surprises of 18.18% and 2.32%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock? |
Vaxart Appoints Edward Berg as Senior Vice President and General CounselPharmaceutical Industry Veteran Brings Broad Legal Expertise to Vaxart Senior Management Team SOUTH SAN FRANCISCO, Calif., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced the appointment of Edward B. Berg as the Company's first in-house General Counsel, effective today. Mr. Berg has practiced law for more than 30 years and has represented Fortune 500 and mid-cap companies in biotechnology, pharmaceuticals and life sciences. He joins Vaxart from BioMarin Pharmaceutic |
Is Vaxart Stock a Buy Now?On the other hand, picking a stock others have largely abandoned could yield impressive returns if the company manages to get back in the good graces of investors. With that in mind, let's look at a biotech company whose shares have been pummeled lately: Vaxart (NASDAQ: VXRT). Vaxart takes a different approach to vaccination: The company focuses on developing oral vaccines. |